1. Home
  2. ANET vs AMGN Comparison

ANET vs AMGN Comparison

Compare ANET & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arista Networks Inc.

ANET

Arista Networks Inc.

HOLD

Current Price

$151.87

Market Cap

173.1B

ML Signal

HOLD

Logo Amgen Inc.

AMGN

Amgen Inc.

HOLD

Current Price

$346.70

Market Cap

188.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANET
AMGN
Founded
2004
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.1B
188.0B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
ANET
AMGN
Price
$151.87
$346.70
Analyst Decision
Strong Buy
Hold
Analyst Count
17
20
Target Price
$173.71
$348.05
AVG Volume (30 Days)
6.0M
2.3M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
2.87%
EPS Growth
23.32
88.23
EPS
2.75
14.23
Revenue
$9,005,700,000.00
$25,424,000,000.00
Revenue This Year
$29.10
$4.97
Revenue Next Year
$21.80
$2.49
P/E Ratio
$53.65
$24.66
Revenue Growth
28.60
8.83
52 Week Low
$66.59
$265.66
52 Week High
$164.94
$391.29

Technical Indicators

Market Signals
Indicator
ANET
AMGN
Relative Strength Index (RSI) 65.95 44.10
Support Level $138.18 $344.95
Resistance Level $163.81 $353.25
Average True Range (ATR) 5.59 7.53
MACD 3.00 0.38
Stochastic Oscillator 99.16 52.25

Price Performance

Historical Comparison
ANET
AMGN

About ANET Arista Networks Inc.

Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: